Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
159.26
-2.07 (-1.28%)
Streaming Delayed Price
Updated: 9:40 AM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
331,156
Open
159.85
Bid (Size)
159.17 (1)
Ask (Size)
159.27 (1)
Prev. Close
161.33
Today's Range
159.00 - 160.09
52wk Range
143.13 - 175.97
Shares Outstanding
2,628,679,824
Dividend Yield
2.99%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Today 7:00 EDT
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Via
InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
Performance
YTD
-0.44%
-0.44%
1 Month
+8.75%
+8.75%
3 Month
+10.15%
+10.15%
6 Month
+0.31%
+0.31%
1 Year
-4.94%
-4.94%
More News
Read More
Q3’s Rising Stars: 3 Dow Stocks for Your Must-Watch List
July 30, 2024
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
A Closer Look at 14 Analyst Recommendations For Johnson & Johnson
July 30, 2024
Via
Benzinga
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
July 30, 2024
Via
MarketBeat
Topics
ETFs
Johnson & Johnson Unusual Options Activity For July 29
July 29, 2024
Via
Benzinga
Looking Into Johnson & Johnson's Recent Short Interest
July 25, 2024
Via
Benzinga
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
July 29, 2024
From
Johnson & Johnson
Via
Business Wire
Stocks Going Ex Dividend In August 2024
July 29, 2024
Via
Talk Markets
7 Long-Term Stocks to Buy on the Dip: July 2024
July 27, 2024
Via
InvestorPlace
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
July 27, 2024
Via
The Motley Fool
Topics
Lawsuit
Exposures
Financial
Legal
Check Out What Whales Are Doing With JNJ
July 24, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 26, 2024
Via
Benzinga
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
July 26, 2024
From
Beasley Allen Law Firm
Via
Business Wire
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
July 26, 2024
From
Ad Hoc Group of Counsel
Via
Business Wire
3 Stocks Reeling From Ruined Reputations: Can They Recover?
July 25, 2024
Via
InvestorPlace
3 Beaten-Down Value Stocks Poised for a Massive Comeback: July 2024
July 25, 2024
Via
InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
July 24, 2024
Via
Benzinga
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
July 23, 2024
From
Johnson & Johnson
Via
Business Wire
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
July 23, 2024
Via
Benzinga
Exposures
Product Safety
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
July 22, 2024
Via
Benzinga
Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
July 22, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
July 22, 2024
From
Beasley Allen Law Firm
Via
Business Wire
Four Stocks To Watch This Week - Monday, July 22
July 22, 2024
Via
Talk Markets
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
July 22, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.